NSE ScannerHospitals & Diagnostics · Medical/Nursing Services · NSE: SURAKSHA · data 2026-11-01
Suraksha Diagnostic Ltd.
In plain words
Price: 12.1% below its 52-week high of ₹360.
Delivery: 49.1% of traded shares were kept for delivery over the last 10 sessions, against 51.2% over the last 60.
Latest results: a net profit of ₹13 cr for the quarter ended Jun 2026 (+38.4% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹325 cr |
| Net profit (last 12 months) | ₹36 cr |
| Sales growth, 3 years (yearly) | 17.7% |
| Profit growth, 3 years (yearly) | 70.3% |
At a glance
Promoters 49.1% (+0.1 pts in a year), pledged 0.1%, institutions 35.5%.
P/E 46.0, dividend yield 0.2%. Price relative to earnings and book value (low is cheaper, not better).
ROE 14.1%, ROCE 15.1%, operating margin 18.2%: how much profit it earns on the money it uses.
Debt/equity 0.53, Profit growth 70.3% and sales growth 17.7% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Profit grew 70.3% a year over 3 years.
- Promoters have pledged 0.1% of their shares.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
SURAKSHA Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹87.65 crore, up 20.7% YoY and up 7.7% QoQ.
Net profit was ₹13.01 crore, up 38.4% YoY and up 107.2% QoQ.
Operating margin was 34.7% (32.7% a year ago).
EPS was ₹2.5, up 38.9% YoY and up 106.6% QoQ.
SURAKSHA के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹87.65 करोड़; पिछले साल की तुलना में 20.7% की बढ़त, पिछली तिमाही की तुलना में 7.7% की बढ़त।
शुद्ध मुनाफ़ा: ₹13.01 करोड़; पिछले साल की तुलना में 38.4% की बढ़त, पिछली तिमाही की तुलना में 107.2% की बढ़त।
ऑपरेटिंग मार्जिन: 34.7% (एक साल पहले 32.7%)।
EPS: ₹2.5; पिछले साल की तुलना में 38.9% की बढ़त, पिछली तिमाही की तुलना में 106.6% की बढ़त।
SURAKSHAના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹87.65 કરોડ; ગયા વર્ષની સરખામણીએ 20.7% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 7.7% વધારો.
ચોખ્ખો નફો: ₹13.01 કરોડ; ગયા વર્ષની સરખામણીએ 38.4% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 107.2% વધારો.
ઓપરેટિંગ માર્જિન: 34.7% (એક વર્ષ પહેલાં 32.7%).
EPS: ₹2.5; ગયા વર્ષની સરખામણીએ 38.9% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 106.6% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
19/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 7/30: Delivery 48.2% over the last 20 sessions vs 39.2% in the 40 before (1.23x); shares delivered per day 0.23x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 7/15: 3 schemes hold it, about ₹209 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Dividend ● Results
- 15 Sept 26Dividend Dividend ₹0.5 (ex-date) +0.9% next session
- 13 Aug 26Results Q1 FY27 results: profit +38.4% YoY +12.8% next session
- 21 May 26Results Q4 FY26 results: profit −15.0% YoY +2.7% next session
- 5 Feb 26Results Q3 FY26 results: profit +25.8% YoY +1.0% next session
- 10 Nov 25Results Q2 FY26 results: profit −13.1% YoY -1.8% next session
- 8 Aug 25Results Q1 FY26 results: net profit ₹9.4 cr +2.2% next session
- 28 May 25Results Q4 FY25 results: net profit ₹7.4 cr +0.2% next session
- 8 Feb 25Results Q3 FY25 results: net profit ₹6 cr -4.6% next session
- 21 Dec 24Results Q2 FY25 results: net profit ₹10.3 cr -1.9% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹88 cr | ₹13 cr | +38.4% | 34.7% | 2.5 |
| Mar 2026 | ₹81 cr | ₹6 cr | -15.0% | 29.9% | 1.21 |
| Dec 2025 | ₹78 cr | ₹8 cr | +25.8% | 29.8% | 1.44 |
| Sept 2025 | ₹79 cr | ₹9 cr | -13.1% | 30.6% | 1.73 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 49.10% | 49.10% | 49.10% | 49.00% |
| Foreign institutions (FII) | 13.97% | 13.47% | 13.46% | 13.46% |
| Domestic institutions (DII) | 21.56% | 23.23% | 23.14% | 22.57% |
| Mutual funds | 20.16% | 20.05% | 19.79% | 19.45% |
| Retail investors | 10.07% | 10.22% | 10.34% | 10.86% |
| Number of shareholders | 60,792 | 64,866 | 67,107 | 70,963 |
Common questions
What was Suraksha Diagnostic Ltd.'s latest quarterly profit?
Suraksha Diagnostic Ltd. reported a net profit of ₹13 cr for the quarter ended Jun 2026 (+38.4% on the same quarter a year earlier), on revenue of ₹88 cr.
How much do promoters hold in Suraksha Diagnostic Ltd.?
Promoters held 49.10% of Suraksha Diagnostic Ltd. at the end of Sept 2026, with 0.10% of promoter shares pledged.
Is Suraksha Diagnostic Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.53.
What is Suraksha Diagnostic Ltd.'s P/E ratio?
About 46, based on the last 12 months' earnings and a price of ₹316.35 (data 2026-11-01).
What is the 52-week high and low of Suraksha Diagnostic Ltd.?
The 52-week high is ₹360 and the 52-week low is ₹224.1.
Mutual funds holding Suraksha Diagnostic Ltd.
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 3 schemes holding about ₹209 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| NIPPON INDIA PHARMA FUND | Nippon India Mutual Fund | 1.51% | ₹138 cr |
| ADITYA BIRLA SUN LIFE ELSS TAX SAVER FUND | Aditya Birla Sun Life Mutual Fund | 0.43% | ₹58 cr |
| ADITYA BIRLA SUN LIFE PHARMA & HEALTHCARE FUND | Aditya Birla Sun Life Mutual Fund | 1.10% | ₹12 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Suraksha Diagnostic Ltd. | ₹316.35 | ₹1,653 cr | 46 | — | 14.1% | 15.1% | 0.53 | -2.1% |
| Dr. Agarwal'S Eye Hospital Limited | ₹5,317.5 | ₹2,552 cr | 33.5 | — | 25.2% | 17.4% | 0.94 | +13.1% |
| Krsnaa Diagnostics Limited | ₹503.75 | ₹1,635 cr | 17 | — | 10.9% | 9.8% | 0.55 | -36.3% |
| Laxmi Dental Ltd. | ₹177.58 | ₹978 cr | 31.6 | — | 12.8% | 11.4% | 0.05 | -43.3% |
| Unihealth Hospitals Ltd | ₹550.25 | ₹875 cr | 33.1 | 6.3 | 21.4% | 22.7% | 0.24 | +221.8% |
| Max India Ltd | ₹147.22 | ₹828 cr | — | — | -31.8% | -26.9% | 0.24 | -30.6% |
Compare SURAKSHA with DRAGARWQ in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open SURAKSHA in NSE Scanner →